scispace - formally typeset
K

Kenneth Raymond

Researcher at The Chinese University of Hong Kong

Publications -  59
Citations -  1395

Kenneth Raymond is an academic researcher from The Chinese University of Hong Kong. The author has contributed to research in topics: Pharmacokinetics & Cmax. The author has an hindex of 18, co-authored 59 publications receiving 1297 citations. Previous affiliations of Kenneth Raymond include University of London & Guy's Hospital.

Papers
More filters
Journal ArticleDOI

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.

TL;DR: This review paper summarises recent findings with emphases on the molecular mechanisms used to explain these broad drug-drug interactions and explains many of the rifampicin inducing drug- drug interactions.
Journal ArticleDOI

Beta-blockade in heart failure: A comparison of carvedilol with metoprolol

TL;DR: In this paper, the authors compared the long-term clinical efficacy of treatment with metoprolol versus carvedilol in patients with chronic heart failure and found that carvedilols were equally effective in improving symptoms, quality of life, exercise capacity and mean left ventricular (LV) ejection fraction.
Journal ArticleDOI

Beta-glucans in the treatment of diabetes and associated cardiovascular risks

TL;DR: Dietary intake of beta-glucans has been shown to reduce all risk factors to benefit the treatment of diabetes and associated complications and promote wound healing and alleviate ischemic heart injury.
Journal ArticleDOI

Toxicological and pharmacological effects of gadolinium and samarium chlorides.

TL;DR: The pharmacological responses to both chemicals were mainly depressant on all systems studied, and death was associated with cardiovascular collapse coupled with respiratory paralysis, whereas irritation of intact skin and ocular tissues was only transient in nature.
Journal ArticleDOI

Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.

TL;DR: Both the advantages of vasodilating beta blockers over metoprolol for initial treatment of heart failure and the usefulness of ANF and BNF measurements for the assessment of drug effects in heart failure compared to traditional haemodynamic measurements are confirmed.